Ayr Wellness Inc. (AYRWF)
(Delayed Data from OTC)
$2.84 USD
-0.58 (-16.86%)
Updated May 1, 2024 02:42 PM ET
2-Buy of 5 2
A Value C Growth F Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AYRWF 2.84 -0.58(-16.86%)
Will AYRWF be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AYRWF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AYRWF
Is Ayr Wellness Inc. (AYRWF) Stock Outpacing Its Medical Peers This Year?
Why Fast-paced Mover Ayr Wellness Inc. (AYRWF) Is a Great Choice for Value Investors
AYRWF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
Despite Fast-paced Momentum, Ayr Wellness Inc. (AYRWF) Is Still a Bargain Stock
Ayr Wellness Inc. (AYRWF) Reports Q4 Loss, Misses Revenue Estimates
Other News for AYRWF
Schumer eyes more cannabis reforms after ‘historic’ marijuana rescheduling decision
Pot stocks rally snuffed day after DEA marijuana rescheduling development
OMB review of cannabis rescheduling could put measure at risk
DEA to reschedule marijuana as a less dangerous drug: AP
US drug control agency to reschedule marijuana: AP